---
title: "Psychedelic biotechs are moving towards Phase 3 with five companies advancing CNS treatments for depression and anxiety."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277230596.md"
description: "Psychedelic biotechs are advancing towards Phase 3 trials, with five companies focusing on CNS treatments for depression and anxiety. Helus Pharma announced on February 27, 2026, that pivotal trials are progressing towards regulatory approval, offering hope for patients who have not responded to traditional therapies. This marks a significant shift in mental health care, potentially leading to new effective treatment options for those suffering from these conditions."
datetime: "2026-02-27T16:46:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277230596.md)
  - [en](https://longbridge.com/en/news/277230596.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277230596.md)
---

# Psychedelic biotechs are moving towards Phase 3 with five companies advancing CNS treatments for depression and anxiety.

Helus Pharma, in Vancouver, BC, issued a statement on February 27, 2026, reporting that psychedelic compounds are making progress towards regulatory approval. Pivotal trials in treating depression and anxiety that have not responded to traditional treatments are moving forward in late-stage development. These achievements are significant for the mental health industry, showcasing potential breakthroughs in alternative therapies. The innovations in treatment come as a response to the ineffectiveness of current treatments on individuals with depression and anxiety. The progress offers hope for those who have not found relief through conventional methods. Such advancements in psychedelic compounds highlight the changing landscape of mental health care and may lead to new, effective options for patients.

### Related Stocks

- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [HEPA.US](https://longbridge.com/en/quote/HEPA.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [426CVR015TMP.US](https://longbridge.com/en/quote/426CVR015TMP.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [HELP.US](https://longbridge.com/en/quote/HELP.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [ZAWYA: CE-Ventures announces acquisition of portfolio company CrossBridge Bio by Eli Lilly](https://longbridge.com/en/news/282695762.md)
- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)
- [Sana Announces Strategic Collaboration With Mayo Clinic For Developing Type-1 Diabetes Therapy SC451](https://longbridge.com/en/news/282645188.md)
- [Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive](https://longbridge.com/en/news/282775123.md)
- [Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial](https://longbridge.com/en/news/282842343.md)